• 1. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 2. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 3. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 4. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 5. Alt-proteins: A promising future

Introduction to 6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester (CAS No. 1016163-41-9)

6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester, identified by the Chemical Abstracts Service Number (CAS No.) 1016163-41-9, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic organic molecule belongs to the benzimidazole family, which has garnered considerable attention due to its diverse biological activities and potential therapeutic applications. The presence of a methoxy group at the 6-position and a methyl ester at the 2-position introduces unique electronic and steric properties, making it a valuable scaffold for drug discovery and molecular design.

The benzimidazole core is a privileged structure in medicinal chemistry, known for its role in various pharmacological interventions. Compounds derived from benzimidazole have been extensively studied for their antimicrobial, antiviral, anti-inflammatory, and anticancer properties. Among these derivatives, 6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester stands out due to its structural modifications that enhance binding affinity and metabolic stability. These features are critical for developing novel therapeutic agents with improved efficacy and reduced side effects.

In recent years, there has been a surge in research focused on optimizing benzimidazole derivatives for clinical use. The methoxy substituent at the 6-position of 6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester plays a pivotal role in modulating the compound's pharmacokinetic profile. This group not only influences the molecule's solubility but also participates in hydrogen bonding interactions with biological targets, thereby enhancing its bioactivity. The methyl ester functionality at the 2-position further contributes to the compound's versatility, allowing for easy derivatization through hydrolysis or transesterification reactions to generate pharmacologically relevant analogs.

One of the most compelling aspects of 6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester is its potential as an intermediate in the synthesis of more complex bioactive molecules. Researchers have leveraged this compound to develop novel inhibitors targeting enzymes involved in cancer progression, such as poly(ADP-ribose) polymerases (PARPs) and cyclin-dependent kinases (CDKs). The benzimidazole scaffold provides a rigid framework that can be fine-tuned through structural modifications to achieve high selectivity and potency against specific disease-related pathways.

Recent advancements in computational chemistry have further accelerated the discovery of new derivatives of 6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester. Molecular modeling techniques, such as molecular dynamics simulations and quantum mechanical calculations, have enabled researchers to predict the binding modes of this compound with various biological targets with remarkable accuracy. These insights have guided the design of next-generation analogs with enhanced pharmacological properties. For instance, studies have shown that subtle changes in the substitution pattern can significantly alter the compound's affinity for certain enzymes, leading to improved therapeutic outcomes.

The pharmaceutical industry has also recognized the potential of 6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester as a building block for drug development. Its structural features make it an ideal candidate for generating libraries of compounds for high-throughput screening (HTS) campaigns. By systematically varying substituents on the benzimidazole core, researchers can identify novel lead compounds with promising biological activity. This approach has been successfully employed in several drug discovery programs aimed at addressing unmet medical needs.

In addition to its applications in oncology, 6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester has shown promise in other therapeutic areas. For example, it has been investigated as a potential scaffold for developing antiviral agents targeting RNA viruses. The benzimidazole moiety's ability to interact with viral proteases and polymerases makes it an attractive candidate for inhibiting viral replication cycles. Furthermore, derivatives of this compound have been explored for their antimicrobial properties, offering new strategies against resistant bacterial strains.

The synthesis of 6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester involves multi-step organic reactions that highlight its synthetic utility. The process typically begins with the condensation of o-hydroxybenzaldehyde with guanidine hydrochloride under basic conditions to form benzimidazole. Subsequent functionalization at the 6-position with a methoxy group introduces the desired electronic properties. The introduction of the methyl ester at the 2-position is achieved through esterification reactions, often employing methanol in the presence of an acid catalyst. These synthetic pathways are well-documented and can be adapted for large-scale production.

The chemical stability of 6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester under various storage conditions is another critical consideration in pharmaceutical applications. Studies have demonstrated that this compound remains stable under controlled temperature and humidity conditions, ensuring its integrity during transport and storage. However, exposure to extreme pH conditions or prolonged UV irradiation may lead to degradation products. Therefore, proper handling and storage protocols must be followed to maintain its efficacy.

From a regulatory perspective, 6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester must comply with Good Manufacturing Practices (GMP) and other quality standards set by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Documentation of synthesis routes, purity specifications, and stability data is essential for regulatory submissions supporting clinical trials or commercialization efforts. Collaborative efforts between chemists, pharmacologists, and regulatory experts ensure that this compound meets stringent safety and efficacy requirements before reaching patients.

The future prospects of 6-methoxy-1H-Benzimidazole-2-carboxylic acid methyl ester are promising, given its versatility as a pharmacophore and intermediate in drug development. Ongoing research aims to expand its applications by exploring novel derivatives with enhanced bioactivity against various diseases. Innovations in synthetic methodologies will further streamline access to this compound and its analogs, facilitating faster translation from bench to bedside.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)